GENinCode PLC

GENI

Company Profile

  • Business description

    GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.

  • Contact

    Oxford Science Park
    John Eccles House, Robert Robertson Avenue
    OxfordOX4 4GP
    GBR

    T: +44 1865676125

    E: [email protected]

    https://www.genincode.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    36

Stocks News & Analysis

stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.
stocks

ChatGPT enters the retail space and one company surges

Investors cheer the ability to purchase directly from ChatGPT.
stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,136.6015.100.17%
CAC 407,966.9571.010.90%
DAX 4024,113.62232.900.98%
Dow JONES (US)46,418.4920.600.04%
FTSE 1009,446.4396.001.03%
HKSE26,855.56232.680.87%
NASDAQ22,730.3070.290.31%
Nikkei 22544,550.85381.78-0.85%
NZX 50 Index13,433.99141.631.07%
S&P 5006,702.6714.210.21%
S&P/ASX 2008,845.7012.300.14%
SSE Composite Index3,882.7820.250.52%

Market Movers